CMPX
Compass Therapeutics, Inc.
Biotechnology
Market Cap$330M
5Y Perf.-73.6%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
CMPX vs IMVT
Revenue, margins, valuation, and 5-year total return — side by side.
IMVT
Immunovant, Inc.
Biotechnology
Market Cap$5.83B
5Y Perf.+82.8%
CMPX vs IMVT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | CMPX | IMVT |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $330M | $5.83B |
| Revenue (TTM) | $0.00 | $0.00 |
| Net Income (TTM) | $-66M | $-464M |
| Total Debt | $10M | $98K |
| Cash & Equiv. | $31M | $714M |
CMPX vs IMVT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
CMPX
IMVT
| Stock | Apr 21 | May 26 | Return |
|---|---|---|---|
| Compass Therapeutic… (CMPX) | 100 | 26.4 | -73.6% |
| Immunovant, Inc. (IMVT) | 100 | 182.8 | +82.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: CMPX vs IMVT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: CMPX and IMVT are tied at the top with 2 categories each — the right choice depends on your priorities. Immunovant, Inc. is the stronger pick specifically for growth and revenue expansion and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
CMPX
Compass Therapeutics, Inc.
The Income Pick
CMPX has the current edge in this matchup, primarily because of its strength in income & stability and growth exposure.
- beta 1.35
- Rev growth -100.0%, EPS growth -16.7%
- Lower volatility, beta 1.35, Low D/E 5.0%, current ratio 15.02x
Best for: income & stability and growth exposure
IMVT
Immunovant, Inc.
The Long-Run Compounder
IMVT is the clearest fit if your priority is long-term compounding.
- 188.1% 10Y total return vs CMPX's -78.2%
- -21.3% revenue growth vs CMPX's -100.0%
- +107.2% vs CMPX's +9.4%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | IMVT | -21.3% revenue growth vs CMPX's -100.0% |
| Stability / Safety | CMPX | Beta 1.35 vs IMVT's 1.37 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | IMVT | +107.2% vs CMPX's +9.4% |
| Efficiency (ROA) | CMPX | -38.0% ROA vs IMVT's -44.1% |
CMPX vs IMVT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLIMVTLAGGINGCMPX
CMPXCompass Therapeutics,…
1leads
IMVTImmunovant, Inc.
2leads
6 Total Categories
CATEGORYLEADERvs CMPXMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
IMVT1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
CMPX4/7
Total Returns1Y, 3Y, 5Y total returns with dividends
IMVT6/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
IMVT leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
CMPX and IMVT operate at a comparable scale, with $0 and $0 in trailing revenue.
| Metric | CMPXCompass Therapeut… | IMVTImmunovant, Inc. |
|---|---|---|
| RevenueTrailing 12 months | $0 | $0 |
| EBITDAEarnings before interest/tax | -$54M | -$487M |
| Net IncomeAfter-tax profit | -$66M | -$464M |
| Free Cash FlowCash after capex | -$49M | -$423M |
| Gross MarginGross profit ÷ Revenue | — | — |
| Operating MarginEBIT ÷ Revenue | — | — |
| Net MarginNet income ÷ Revenue | — | — |
| FCF MarginFCF ÷ Revenue | — | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | +18.2% | +19.7% |
IMVT leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — CMPX and IMVT each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | CMPXCompass Therapeut… | IMVTImmunovant, Inc. |
|---|---|---|
| Market CapShares × price | $330M | $5.8B |
| Enterprise ValueMkt cap + debt − cash | $309M | $5.1B |
| Trailing P/EPrice ÷ TTM EPS | -4.40x | -10.50x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — |
| Price / BookPrice ÷ Book value/share | 1.48x | 6.14x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — CMPX and IMVT each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
CMPX leads this category, winning 4 of 7 comparable metrics.
Profitability & Efficiency
CMPX delivers a -43.6% return on equity — every $100 of shareholder capital generates $-44 in annual profit, vs $-47 for IMVT. IMVT carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to CMPX's 0.05x. On the Piotroski fundamental quality scale (0–9), CMPX scores 3/9 vs IMVT's 2/9, reflecting mixed financial health.
| Metric | CMPXCompass Therapeut… | IMVTImmunovant, Inc. |
|---|---|---|
| ROE (TTM)Return on equity | -43.6% | -47.1% |
| ROA (TTM)Return on assets | -38.0% | -44.1% |
| ROICReturn on invested capital | -41.3% | — |
| ROCEReturn on capital employed | -43.2% | -66.1% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 2 |
| Debt / EquityFinancial leverage | 0.05x | 0.00x |
| Net DebtTotal debt minus cash | -$21M | -$714M |
| Cash & Equiv.Liquid assets | $31M | $714M |
| Total DebtShort + long-term debt | $10M | $98,000 |
| Interest CoverageEBIT ÷ Interest expense | — | — |
CMPX leads this category, winning 4 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
IMVT leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in IMVT five years ago would be worth $17,386 today (with dividends reinvested), compared to $3,522 for CMPX. Over the past 12 months, IMVT leads with a +107.2% total return vs CMPX's +9.4%. The 3-year compound annual growth rate (CAGR) favors IMVT at 14.1% vs CMPX's -19.0% — a key indicator of consistent wealth creation.
| Metric | CMPXCompass Therapeut… | IMVTImmunovant, Inc. |
|---|---|---|
| YTD ReturnYear-to-date | -64.2% | +10.7% |
| 1-Year ReturnPast 12 months | +9.4% | +107.2% |
| 3-Year ReturnCumulative with dividends | -46.9% | +48.4% |
| 5-Year ReturnCumulative with dividends | -64.8% | +73.9% |
| 10-Year ReturnCumulative with dividends | -78.2% | +188.1% |
| CAGR (3Y)Annualised 3-year return | -19.0% | +14.1% |
IMVT leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
Evenly matched — CMPX and IMVT each lead in 1 of 2 comparable metrics.
Risk & Volatility
CMPX is the less volatile stock with a 1.35 beta — it tends to amplify market swings less than IMVT's 1.37 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. IMVT currently trades 95.3% from its 52-week high vs CMPX's 26.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | CMPXCompass Therapeut… | IMVTImmunovant, Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.35x | 1.37x |
| 52-Week HighHighest price in past year | $6.88 | $30.09 |
| 52-Week LowLowest price in past year | $1.61 | $13.36 |
| % of 52W HighCurrent price vs 52-week peak | +26.9% | +95.3% |
| RSI (14)Momentum oscillator 0–100 | 24.4 | 55.7 |
| Avg Volume (50D)Average daily shares traded | 7.5M | 1.4M |
Evenly matched — CMPX and IMVT each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates CMPX as "Buy" and IMVT as "Buy". Consensus price targets imply 505.7% upside for CMPX (target: $11) vs 58.7% for IMVT (target: $46).
| Metric | CMPXCompass Therapeut… | IMVTImmunovant, Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $11.20 | $45.50 |
| # AnalystsCovering analysts | 15 | 23 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
IMVT leads in 2 of 6 categories (Income & Cash Flow, Total Returns). CMPX leads in 1 (Profitability & Efficiency). 2 tied.
Best OverallImmunovant, Inc. (IMVT)Leads 2 of 6 categories
Loading custom metrics...
CMPX vs IMVT: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is CMPX or IMVT a better buy right now?
Analysts rate Compass Therapeutics, Inc.
(CMPX) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — CMPX or IMVT?
Over the past 5 years, Immunovant, Inc.
(IMVT) delivered a total return of +73. 9%, compared to -64. 8% for Compass Therapeutics, Inc. (CMPX). Over 10 years, the gap is even starker: IMVT returned +188. 1% versus CMPX's -78. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — CMPX or IMVT?
By beta (market sensitivity over 5 years), Compass Therapeutics, Inc.
(CMPX) is the lower-risk stock at 1. 35β versus Immunovant, Inc. 's 1. 37β — meaning IMVT is approximately 2% more volatile than CMPX relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 5% for Compass Therapeutics, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — CMPX or IMVT?
On earnings-per-share growth, the picture is similar: Compass Therapeutics, Inc.
grew EPS -16. 7% year-over-year, compared to -45. 2% for Immunovant, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — CMPX or IMVT?
Compass Therapeutics, Inc.
(CMPX) is the more profitable company, earning 0. 0% net margin versus 0. 0% for Immunovant, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CMPX leads at 0. 0% versus 0. 0% for IMVT. At the gross margin level — before operating expenses — CMPX leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — CMPX or IMVT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is CMPX or IMVT better for a retirement portfolio?
For long-horizon retirement investors, Immunovant, Inc.
(IMVT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+188. 1% 10Y return). Both have compounded well over 10 years (IMVT: +188. 1%, CMPX: -78. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between CMPX and IMVT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.